The Global Drug sales of Xeljanz stood at USD 1,703 Millions in 2023
The indicator recorded a historical decline (CAGR) of11% between 2020 to 2023 and is expected to decline by ...
GlobalData projects the indicator to decline at a CAGR of...
Tofacitinib (Xeljanz) is an immunosuppressant. It is formulated as film coated tablets, tablets, coated tablets and solution for oral route of administration.
Mechanism of Action
Tofacitinib is an immunosuppressive inhibitor of JAK-3. JAK-3 has been shown to play a key role in cytokine signaling via gammac. In cell-based assays, Tofacitinib has been shown to inhibit JAK-3 with functional selectivity over JAK-2. It is expected to overcome these limitations by selectively targeting JAK3, which is expressed generally only in immune cells and only bound by gamma-chain-bearing cytokine receptors involved in the JAK/STAT signaling pathway. By inhibiting this enzyme, which affects the signaling of multiple cytokines (proteins released by cells to communicate with other cells) that are involved in a broad spectrum of inflammatory and autoimmune diseases.
Xeljanz Overview
Xeljanz is marketed for the treatment of several indications in Cardiovascular, Dermatology, Gastrointestinal, Genetic Disorders, Immunology, Infectious Disease, Musculoskeletal Disorders, and Ophthalmology therapy areas.
Tofacitinib is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers. It may be used as monotherapy or in combination with methotrexate or other nonbiologic disease- modifying antirheumatic drugs (DMARDs) and for the treatment of adults with moderately to severely active ulcerative colitis. It is also indicated for the treatment of active polyarticular course juvenile idiopathic arthritis (pcJIA) in patients 2 years of age and older who have had an inadequate response or intolerance to one or more TNF blockers and Celiac Disease. It is also indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers or other disease-modifying antirheumatic drugs (DMARDs). XELJANZ is indicated for the treatment of adult patients with active ankylosing spondylitis (AS) who have had an inadequate response or intolerance to one or more TNF blockers.
Xeljanz was first approved in 2012 and is sold globally including the US, the UK, Australia, Germany, and Japan by several pharma giants including Pfizer Inc. Xeljanz drug sales recorded a high-single digit Year on Year growth in 2021. Xeljanz drug sales include the historical sales that are derived from company financial reports, and consensus forecasts are calculated based on company-specific broker reports as well as GlobalData’s proprietary methodology.
United States of America
China
United States of America
United States of America
United States of America
United States of America
France
United States of America
United States of America
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer